Cognigenics' Intranasal CRISPR Delivery Bypasses Blood-Brain Barrier; Potential Breakthrough Therapeutic
- S&P 500 edges lower as investors hold their breath ahead of economic data
- BofA lifts S&P 500's year-end target to 5,400
- Goldman Sachs: Today's growth stock rally is unlike 90's tech bubble
- Apple hit with $2 billion EU antitrust fine in Spotify case, will appeal
- JetBlue, Spirit Airlines call off $3.8 billion merger on antitrust hurdle
Study: method reduced anxiety with no apparent toxicity or neurologic damage
BOISE, Idaho--(BUSINESS WIRE)-- Cognigenics CEO John L. Mee announces breakthrough results from an animal study published today in PNAS Nexus. The findings point to the potential of non-invasively delivering neuromodulating gene therapies to the brain for chronic mental health conditions using adeno-associated viruses introduced intranasally.
"Our patent-pending CRISPR/Cas9 delivery system enabled us to bypass the blood-brain barrier by intranasally administering therapeutics to reach the central nervous system via the neural pathways in the nasal cavity,” said Director of Preclinical Studies Troy Rohn, PhD, principal investigator of the study. “In the study, a single dose significantly reduced anxiety in mice, demonstrating that complex behavioral traits can be directly modified by this non-invasive technique.”
Chief Medical Officer Barry J. Linder, MD added, "While our findings are preliminary, they may lead to a new class of long-lasting therapeutics with fewer side effects than SSRIs for mental health conditions including anxiety, depression and ADHD, as well as for some genetic conditions."
Significant reduction in anxiety
The animal study tested a platform of CRISPR/Cas9 utilizing two adeno-associated viruses (AAVs) to deliver anti-anxiety reagents in vivo to the part of the brain that is overactive in anxiety. The method requires two delivery vectors because of the limited cargo capacity of the viruses. Each virus was modified using Cognigenics' proprietary CRISPR gene-editing technology.
Treated mice showed 35.7% and 14.8% decreases in two standard measures of anxiety.
No toxicity or neurologic damage
Importantly, there was no evidence of toxicity at any concentration following treatment, and neurons were healthy.
About CRISPR technology
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary genetic technology that allows precise editing of DNA. It functions like molecular scissors, cutting DNA at a specific location and allowing researchers to add, remove, or replace specific sections of genetic code. CRISPR has the potential for treating a wide range of genetic diseases and mental health conditions.
Founded in 2019, Cognigenics works at the forefront of genetic neuroengineering through patent-pending CRISPR technology to precisely and noninvasively target and modulate the underlying neural circuits responsible for mental health disorders such as anxiety, depression, ADHD, and some forms of cognitive impairment.
Learn more at www.cognigenics.io.
Dean Radin, PhD
John L. Mee
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MethaneSAT Now in Orbit after SpaceX Launches Groundbreaking Mission to Protect the Climate
- AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
- Chubb Limited Announces Pricing of $1 Billion Senior Notes Offering by Subsidiary
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!